SCHEMBL22999977

SCHEMBL22999977

Cc1ccc(Nc2ncc3c(n2)CNC3)cc1C#N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.44
BTK Q06187 5/20 0.42
CDK5 Q00535 3/20 0.41
CCNA2 P20248 2/20 0.41
CDK2 P24941 2/20 0.41
CDK5R1 Q15078 2/20 0.41
KDR P35968 5/20 0.41
CDK1 P06493 4/20 0.41
CCNB1 P14635 1/20 0.40
MAOB P27338 1/20 0.39
SYK P43405 1/20 0.39
AURKA O14965 2/20 0.38
SLC2A1 P11166 1/20 0.38
IKBKE Q14164 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
DAPK3 O43293 1/20 0.37
JAK2 O60674 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23021006 0.85 L3MBTL1 (0.48) GRM5BTKCDK5CCNA2CDK2
Hydrochloric Acid SCHEMBL22999706 0.84 L3MBTL1 (0.47) GRM5BTKCDK5CCNA2CDK2
SCHEMBL23021018 0.82 CDK2 (0.43) GRM5BTKCDK5CCNA2CDK2
Hydrochloric Acid SCHEMBL22999658 0.81 CDK2 (0.42) GRM5BTKCDK5CCNA2CDK2
SCHEMBL23000014 0.80 GRM5 (0.54) GRM5CDK5CCNA2CDK2CDK5R1
SCHEMBL23021015 0.80 BRD4 (0.44) CDK5CCNA2CDK2CDK5R1KDR
SCHEMBL23021023 0.80 CDK2 (0.43) GRM5BTKCDK5CCNA2CDK2
SCHEMBL23020730 0.79 ULK1 (0.45) BTKCDK5CCNA2CDK2CDK5R1
SCHEMBL23021156 0.79 CDK2 (0.63) GRM5CDK5CCNA2CDK2CDK5R1
Hydrochloric Acid SCHEMBL22999614 0.77 CDK2 (0.62) GRM5CDK5CCNA2CDK2CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021032323-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES GALAPAGOS NV (BE) 2021-02-25 WO disclosed
EP-3782997-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES Galapagos N.V. (BE) 2021-02-24 EP disclosed
EP-3782997-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES Galapagos N.V. (BE) 2021-02-24 EP disclosed